Table 2.

Univariable and multivariable linear regression analysis for determinants of serum T₅₀

	Univariable analysis			Multivariable analysis
	Beta	R²	P value	Beta	Partial R2	P value
Age (years)	0.024	0.000	0.911
Sex	22.435	0.029	<0.001	27.097	0.026	<0.001
Smoking	−22.579	0.017	<0.001	−18.998	0.015	0.003
Alcohol use	8.140	0.003	0.108
BMI (kg/m²)	−0.492	0.002	0.240
SBP (mm Hg)	−0.253	0.004	0.068	−0.354	0.004	0.025
DBP (mm Hg)	−0.382	0.003	0.123
Duration of diabetes (months)	−1.061	0.007	0.011
HbA1c (mmol/mol)	−1.073	0.020	<0.001	−1.115	0.015	<0.001
Total cholesterol (mmol/L)	1.390	0.000	0.530	−28.616	0.013	<0.001
HDL cholesterol (mmol/L)	−7.930	0.002	0.188
Total cholesterol/HDL ratio	2.300	0.001	0.248	−9.531	0.006	0.030
LDL cholesterol (mmol/L)	6.323	0.006	0.015	43.982	0.020	<0.001
Triglycerides (mmol/L)	−1.026	0.000	0.644	12.888	0.007	0.009
History of macrovascular event	−3.165	0.000	0.521
History of AP	9.491	0.001	0.245
History of MI	−0.971	0.000	0.899
History of PCI	−19.443	0.002	0.150
History of CABG	−11.923	0.002	0.227
History of TIA	14.635	0.002	0.220
History of stroke	−4.294	0.000	0.631
Microvascular complication	−2.448	0.000	0.604
Retinopathy	−23.677	0.006	0.029	−0.075	0.004	0.036
Peripheral neuropathy	−0.557	0.000	0.920
Albuminuria	0.541	0.000	0.931
eGFR (mL/min/1.73 m²)	−0.036	0.001	0.416
Albumin/creatinin ratio	−0.703	0.005	0.037
Diet, % (N)	6.044	0.001	0.264
Oral blood glucose lowering drugs, % (N)	−1.057	0.000	0.838
Insulin therapy, % (N)	−16.035	0.007	0.012
Cholesterol-lowering drugs, % (N)	4.477	0.001	0.399
Antihypertensive therapy, % (N)	−4.160	0.001	0.485

AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic attack.